Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ATF4 | P18848 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104760 | 1.00 | MAOB (0.49) | MAOBTACR2KDM4EPOLBTSHR | |
| SCHEMBL5101810 | 0.94 | TACR2 (0.49) | MAOBTACR2KDM4ETSHRATF4 | |
| SCHEMBL6912913 | 0.86 | MAOB (0.48) | MAOBKDM4EPOLBTSHRATF4 | |
| SCHEMBL6912921 | 0.86 | MAOB (0.48) | MAOBKDM4EPOLBTSHRATF4 | |
| SCHEMBL4763329 | 0.83 | MAOB (0.57) | MAOBKDM4EPOLBTSHRSIGMAR1 | |
| SCHEMBL443699 | 0.81 | MAOB (0.55) | MAOBKDM4EPOLBTSHRSIGMAR1 | |
| SCHEMBL1812570 | 0.80 | PSMB1 (0.61) | KDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL1807911 | 0.80 | PSMB1 (0.61) | KDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL445130 | 0.79 | KDM4E (0.55) | MAOBKDM4ETSHRADAM17SIGMAR1 | |
| SCHEMBL14383957 | 0.76 | TSHR (0.53) | MAOBKDM4ETSHRADAM17DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342027-B2 | 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2008-03-11 | — | — | US | disclosed |
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | CTRL, PRCP, CLPP | MAOB 1276/4885TACR2 3647/4885KDM4E 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.